Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Momenta Continues Its Transition

TheMotleyFool

0 0

Momenta Continues Its TransitionPhoto, wide shot, wide-angle lens, Pharmaceutical company, Midday, harsh overhead sunlight, directional sunlightt, photo by Art Wolfe: https://img.midjourneyapi.xyz/temp/7ae4a134-dd01-4c80-a621-18399f5a2541.png

Momenta Pharmaceuticals (NASDAQ: MNTA) continues its transition from a drugmaker specializing in hard-to-make generic drugs to one focused on novel products. The financial numbers aren't going to be pretty during the transition, so investors should focus on the pipeline.

Fortunately, with $380 million in the bank, Momenta has a solid runway to get to at least proof of concept for its novel products.

Metric

Quelle Fool.com

Like: 0

MNTA

Teilen